# Eribulin as an antibody-conjugate payload

Source: https://onco.cc/terms/eribulin-payload/  
OnCo record `eribulin-payload` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Eribulin is a drug that disrupts the scaffolding needed for cell division. Linking it to an antibody changes how it is delivered and needs separate evidence from eribulin given on its own.

## Summary

Farletuzumab ecteribulin, or MORAb-202, combines a folate receptor alpha antibody with eribulin through a cleavable linker. Primary preclinical work reported target-dependent activity, bystander killing in coculture, and activity in breast cancer xenografts. Eribulin represents another tubulin-directed scaffold, not a new biological target beyond tubulin. Evidence and toxicity of the conjugate must be kept separate from those of free eribulin.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: ecteribulin payload; MORAb-202 payload; halichondrin-derived payloads

## Sources

- MORAb-202 in breast cancer models (2021): https://doi.org/10.1111/cas.14898

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Eribulin](https://onco.cc/drugs/eribulin/), [Farletuzumab ecteribulin](https://onco.cc/drugs/farletuzumab-ecteribulin/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/), [Tubulin inhibitor payloads](https://onco.cc/terms/tubulin-inhibitor-payloads/)

---
JSON: https://onco.cc/api/v1/entities/eribulin-payload.json